Using hiPS gene editing to create a tyrosinemia disease model
CRISPR/Cas9 technology enables precise, footprint-free gene editing. By combining CRISPR/Cas9 with human pluripotent stem cells, we can generate disease models that advance our understanding of disease mechanisms and guide development of novel therapeutics. However, creating these models can be quite difficult. Editing genes while concurrently establishing clonal populations can be both inefficient and time consuming.
In this presentation, Dr. Montse Morell talks about the challenges of creating disease models from hiPSCs. She shares a streamlined method for generating iPSC-derived hepatocytes to model tyrosinemia.
Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2021 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.